[
  {
    "ts": "2026-03-01T09:27:54+00:00",
    "headline": "Pfizer Inc. (PFE) and Astellas Pharma Announce Positive Results From the Phase 3 EV-304 Clinical Trial for PADCEVTM",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks under $50 to buy right now. Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. announced on February 27 positive results from the Phase 3 EV-304 clinical trial for PADCEVTM, a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda®, a PD-1 inhibitor, in patients with muscle-invasive bladder […]",
    "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-astellas-pharma-092754566.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "5f430bed-6836-3cc1-a69b-7094c2116876",
      "content": {
        "id": "5f430bed-6836-3cc1-a69b-7094c2116876",
        "contentType": "STORY",
        "title": "Pfizer Inc. (PFE) and Astellas Pharma Announce Positive Results From the Phase 3 EV-304 Clinical Trial for PADCEVTM",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks under $50 to buy right now. Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. announced on February 27 positive results from the Phase 3 EV-304 clinical trial for PADCEVTM, a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda®, a PD-1 inhibitor, in patients with muscle-invasive bladder […]",
        "pubDate": "2026-03-01T09:27:54Z",
        "displayTime": "2026-03-01T09:27:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "RBC Capital Sees Merck (MRK) Returning to Growth Sooner Than Market Expects",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UKiv8LHLxutAA7dDIzr_pw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1v0rnd.QZj0de1gLzaNuAg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-astellas-pharma-092754566.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-astellas-pharma-092754566.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "4503.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-03-01T11:05:00+00:00",
    "headline": "Should You Forget Eli Lilly and Buy This Magnificent High-Yield Dividend Stock Instead?",
    "summary": "Eli Lilly is making headlines in the pharmaceutical sector, but it's a very expensive stock.",
    "url": "https://www.fool.com/investing/2026/03/01/forget-eli-lilly-buy-high-yield-dividend-stock/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "76f26dd5-4140-3a83-984c-001bc9c66133",
      "content": {
        "id": "76f26dd5-4140-3a83-984c-001bc9c66133",
        "contentType": "STORY",
        "title": "Should You Forget Eli Lilly and Buy This Magnificent High-Yield Dividend Stock Instead?",
        "description": "",
        "summary": "Eli Lilly is making headlines in the pharmaceutical sector, but it's a very expensive stock.",
        "pubDate": "2026-03-01T11:05:00Z",
        "displayTime": "2026-03-01T11:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/349bb326235358ac946952f82fa4ba22",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A balance showing Price on one side and Value on the other.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wLESgPBiqP0rgisyQBmoqA--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/349bb326235358ac946952f82fa4ba22.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OIavuQrndNQUreaaQRBlJw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/349bb326235358ac946952f82fa4ba22.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/03/01/forget-eli-lilly-buy-high-yield-dividend-stock/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/forget-eli-lilly-buy-magnificent-110500813.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "INTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-03-01T17:23:00+00:00",
    "headline": "Forget Regencell Bioscience: This Blue Chip Drug Maker Is the Boring Compounder You Need",
    "summary": "Don't follow general market sentiment when it comes to these two stocks.",
    "url": "https://www.fool.com/investing/2026/03/01/forget-regencell-this-bluechip-drug-maker-is/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "889d6cf2-e04d-3000-9bc2-1f3f2ac8061f",
      "content": {
        "id": "889d6cf2-e04d-3000-9bc2-1f3f2ac8061f",
        "contentType": "STORY",
        "title": "Forget Regencell Bioscience: This Blue Chip Drug Maker Is the Boring Compounder You Need",
        "description": "",
        "summary": "Don't follow general market sentiment when it comes to these two stocks.",
        "pubDate": "2026-03-01T17:23:00Z",
        "displayTime": "2026-03-01T17:23:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/cf5d186c8612e09ccd3a5f039df5228c",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Person working at a desk in a home office with a large-screen monitor.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vco2wd9SGDunWoGs557KjQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/cf5d186c8612e09ccd3a5f039df5228c.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oW7njWbGpAM7lt9xcZNXVw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/cf5d186c8612e09ccd3a5f039df5228c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/03/01/forget-regencell-this-bluechip-drug-maker-is/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/forget-regencell-bioscience-blue-chip-172300033.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "RGC"
            },
            {
              "symbol": "INTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]